Foundayo for Weight Loss
Eli Lilly's daily weight loss pill, FDA approved April 2026. The first GLP-1 pill that does not require an empty stomach, a 30-minute wait, or a specific time of day.
Reviewed by GlobalGLP1 editorial team • Drug facts last checked August 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Overview
Foundayo is a once-daily pill from Eli Lilly that was FDA approved in April 2026 for chronic weight management. It is the first GLP-1 medication available as a regular small-molecule tablet, which means it works at any time of day with or without food or water. The active ingredient is orforglipron. In the ATTAIN-1 Phase 3 trial, people on the highest FDA-approved dose lost an average of 12.4% of their body weight over 72 weeks. That is less than injectable Wegovy or Zepbound, but for people who cannot tolerate needles, travel often, or have run into injection supply shortages, the pill format is a real change. Foundayo is approved for adults with obesity (BMI 30 or higher) or with overweight (BMI 27+) plus a weight-related health condition like high blood pressure, type 2 diabetes, or sleep apnea.
How Foundayo Works
Foundayo is the brand name for orforglipron. It works by activating the GLP-1 receptor, the same hunger pathway that Wegovy and Ozempic target with injections. The difference is that Foundayo is a small-molecule drug, so it absorbs reliably as a pill and does not need an empty stomach, a 30-minute wait, or a specific time of day. You take one tablet daily, with or without food or water, whenever fits your routine.
FDA Approval
Foundayo
Chronic weight management in adults
0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg once-daily tablets (escalating dose; 17.2 mg is the maintenance dose)
How You Take It
The full build-up takes a few months. Picking a consistent time each day helps you remember, but skipping a window does not require special timing the way Rybelsus does.
How Much Weight You Can Lose
In the ATTAIN-1 Phase 3 trial, people on the 17.2 mg maintenance dose lost an average of 12.4% of their body weight over 72 weeks, compared to 0.9% with placebo, counting people who stayed on treatment. Counting everyone who started, the figure for the same dose was 11.1%. The FDA label reports average weight loss of 7.4% to 11.1% across the approved tablet doses. For a 200-pound person on the highest dose, 12.4% is roughly 25 pounds.
Side Effects
Common Side Effects
- Nausea (most common during dose increases, usually eases over a few weeks)
- Constipation (common, often helped by fluids and fiber)
- Diarrhea (typically mild and short-lived)
- Vomiting (most common in the first weeks, drops off after the first month)
- Indigestion and heartburn (mild for most people)
- Abdominal pain (usually mild)
- Headache
- Belching and gas
- Fatigue (often improves as your body adjusts)
- Hair thinning (reported by some patients, usually temporary)
Rare but Serious
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, observed in rodents)
- Acute kidney injury (linked to dehydration from severe vomiting or diarrhea)
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Allergic reactions
- Breathing food or liquid into the lungs during surgery under general anesthesia or deep sedation. These drugs slow the stomach down, so tell your surgeon, anesthetist and dentist that you take one before any planned procedure
- Worsening of diabetic eye disease in people with type 2 diabetes who already have retinopathy. The label asks for monitoring; this is not described as a risk for people without diabetes
Managing side effects: Stomach side effects are most common during the first weeks and around each dose increase, then ease as your body adjusts. The slow build-up exists for this reason. Eat smaller meals, stay hydrated (especially important with Foundayo because dehydration from GI side effects can hurt the kidneys), and avoid greasy or very rich foods. If nausea is bad enough that you cannot keep fluids down, contact your provider. They can slow or pause the dose escalation.
Foundayo Cost & Savings (2026)
Savings programs: Foundayo Savings Card: commercially insured patients may pay as little as $25 per month if their plan covers Foundayo. Lilly Cares Patient Assistance Program may cover Foundayo for free for qualifying uninsured patients who meet income limits. Medicare and Medicaid patients are not eligible for the commercial savings card.
Who Should Not Take Foundayo
- Personal or family history of medullary thyroid carcinoma (MTC)
- A rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Allergy to orforglipron or any ingredient in Foundayo
- Pregnancy or planning to become pregnant
- History of inflamed pancreas (pancreatitis), use with caution
- Severe stomach or intestinal disease (gastroparesis)
What to Expect, Month by Month
Most patients notice decreased hunger and smaller portion sizes. Some early nausea is common.
Measurable weight loss begins as the dose escalates to 14.5 mg. Average 2-4% body weight lost during escalation.
On the full 17.2 mg dose. Steady weight loss of about 1 pound per week. GI side effects have usually settled.
Average 8-12% body weight lost. Blood pressure, cholesterol, and blood sugar improvements measurable.
Weight loss plateau near 12.4% average. Maintenance phase begins.
Other Medications to Watch
Can cause dangerously low blood sugar when combined. Your doctor will usually reduce your insulin or sulfonylurea dose when starting Foundayo.
Foundayo slows digestion, which can change how other oral medications absorb. Less of an issue than with injected GLP-1s because the effect is milder, but tell your prescriber about every drug you take.
Slower digestion can change how warfarin absorbs. Your doctor should check your clotting levels (INR) more often when starting Foundayo or changing your dose.
The FDA label tells prescribers to advise anyone on birth control pills to switch to a non-oral method, or add a barrier method such as condoms, for 30 days after starting Foundayo and for 30 days after each dose increase. This is not optional advice in the label, and Foundayo may cause fetal harm. Methods that are not swallowed, such as the patch, ring, implant, injection or IUD, are not affected.
Special Situations
Do not use during pregnancy. Stop Foundayo well before trying to conceive. Animal studies showed harm to the fetus.
No dose change needed at any level, including end-stage kidney disease. Separately, and for everyone rather than kidney patients alone, the label warns that severe vomiting or diarrhea can dehydrate you enough to injure the kidneys, so stay well hydrated, especially during dose increases.
Foundayo is not recommended if you have severe liver impairment (Child-Pugh Class C). That is the wording the label itself uses, in its summary box, and it is not a data gap. No dose change is needed for mild or moderate.
A subgroup analysis of ATTAIN-1 and ATTAIN-2 showed adults 65 and older lost up to 13% of body weight with Foundayo. No dose change needed, but watch for dehydration since GI side effects can hit older adults harder.
Not currently FDA-approved for adolescents. Studies in younger populations are planned.
What Happens If You Stop
No trial has stopped Foundayo and measured what happens, so there is no figure for this drug the way there is for Wegovy and Zepbound, where roughly two thirds of the lost weight came back within a year. What has been studied is close to the reverse: in the ATTAIN-MAINTAIN trial, people who had lost weight on Wegovy or Zepbound switched to Foundayo and held nearly all of it over 52 weeks. That shows Foundayo can hold a loss; it does not tell you what happens when you stop taking it. Regain after stopping is the pattern for every drug in this class, so expect it until there is evidence otherwise.
How to make stopping easier: Build sustainable eating and movement habits while on the medication so you have a foundation when you stop. Some patients transition to a lower maintenance dose long-term, which is easier and cheaper with a daily pill than with weekly injections. Talk with your prescriber before stopping suddenly.
Foundayo FAQs
Foundayo is a daily pill version of a GLP-1 medication. Wegovy and Zepbound are weekly injections. Foundayo produces less weight loss on average. Among people who stayed on treatment the averages were about 12.4% for Foundayo, 16.9% for Wegovy and 22.5% for Zepbound. It removes the needle, refrigeration, and weekly-shot routine entirely. For people who cannot tolerate injections, travel a lot, or want a simpler routine, a pill is a real alternative. Note that Foundayo is not the only one now: the Wegovy pill arrived in January 2026 and is cheaper, though it has to be taken on an empty stomach with a 30-minute wait, which Foundayo does not.
They are the two daily pills approved for weight loss, and they are not the same kind of drug. The Wegovy pill is oral semaglutide, a peptide, so it has to be taken on an empty stomach in the morning with no more than 4 ounces of water, and you wait 30 minutes before eating, drinking or taking anything else. Foundayo is a small molecule, so you take it whenever you like, with or without food. On weight loss the Wegovy pill did better in its trial (about 14% over 64 weeks against about 12.4% for Foundayo over 72 weeks), and it is cheaper at $149 a month to start. Foundayo wins on convenience. Neither has been tested against the other in a single trial, so treat those percentages as coming from separate studies rather than a head-to-head.
Both are GLP-1 pills, but they work differently. Rybelsus is an oral version of injected semaglutide, a peptide, which means it has to be taken on an empty stomach with no food, drink, or other medications for at least 30 minutes after. Foundayo is a small-molecule drug, so it can be taken any time of day, with or without food or water. Foundayo also produced more weight loss in trials.
List price is roughly $700 to $1,000 per month at retail pharmacies. Eli Lilly may roll out a direct-pay option through LillyDirect at a discount once supply stabilizes. Most people will pay less with insurance and the Foundayo Savings Card.
In the ATTAIN-1 trial, people on the 17.2 mg maintenance dose lost an average of 12.4% of their body weight over 72 weeks, compared to 0.9% with placebo. Across the lower approved tablet doses, the FDA label reports average weight loss of 7.4% to 11.1%. Results vary depending on dose, diet, exercise, and how your body responds.
Coverage is rolling out through 2026 as commercial plans update their formularies. Many will cover Foundayo with prior authorization, requiring a BMI of 30 or higher (or 27+ with a weight-related condition). Medicare does not cover GLP-1s for weight loss alone, but coverage may expand for patients with obesity and cardiovascular disease. Medicaid coverage varies by state.
Any licensed doctor or nurse practitioner can prescribe it. In-person and telehealth clinics that prescribe other GLP-1s will typically prescribe Foundayo as well. Use the directory below to find providers in your state.
Nausea, constipation, diarrhea, vomiting, and abdominal pain are the most common. They tend to be worst during the first few weeks and around dose increases. A small number of patients report temporary hair thinning. Severe vomiting or diarrhea can cause dehydration, so contact your provider if you cannot keep fluids down. Foundayo carries the same boxed warning about thyroid C-cell tumors as other GLP-1s, based on rodent studies.
Looking for a Clinic?
Foundayo is a new medication. While our directory does not yet have confirmed Foundayo prescribers, many GLP-1 clinics will prescribe it for eligible patients.
Browse GLP-1 Clinics →Related Foundayo resources
Looking for Foundayo?
Foundayo is a new medication. Our directory does not yet have confirmed Foundayo prescribers, but many of our 3,318 GLP-1 clinics will prescribe it for eligible patients. Browse all clinics or ask any GLP-1 prescriber about availability.
References
Every figure on this page comes from one of the following. Prescribing information is linked on DailyMed, which serves the current label rather than a snapshot of an old one. Trials are linked by DOI.
- Foundayo (orforglipron) tablets: prescribing information
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1) The 72-week trial behind the ~11-12.4% figures.
Drug facts on this page last checked against these sources August 2026.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.